Sign in
CompletedPhase 1/2

Furazolidone Quadruple Regimen Eradicate H. Pylori Infection

Key facts

Who runs it
Liaocheng People's Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
493 people enrolled
Started
1 Aug 2022
Ended
30 Jul 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Furazolidone
  • Clarithromycin
Record updated
12 February 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • H Pylori infection: 13C/14C urea breath test positive or rapid urease test positive or gastric mucosal tissue pathological section HE staining positive or gastric mucosal tissue H. Pylori culture positive or fecal Positive detection of H pylori antigen
  • No previous History of eradication treatment for H pylori
  • Age 18-70 years old

Who cannot take part

  • There are also other serious diseases that affect the evaluation of this study, such as severe coronary heart disease, liver disease, kidney disease, chronic obstructive pulmonary disease, malignant tumors, and psychological disorders
  • Individuals with a history of significant or complex gastrointestinal surgery
  • Individuals who are allergic to the drugs used in this study
  • Pregnant or lactating women
  • Unable to cooperate with this experimenter

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Research protocol:

Read full original descriptionShow less

Experimental group:

First line solution (furazolidone regimen): esomeprazole magnesium 20 mg +colloidal bismuth pectin 200mg+ amoxicillin 1000 mg + furazolidone 100 mg, twice daily, for 14 days.

Patients who is still positive for H. pylori infection after the first line solution select the second line solution (high-dose dual regimen): esomeprazole magnesium 20 mg and amoxicillin 750 mg, 4 times daily, for 14 days.

Control group:

First line solution (clarithromycin regimen): esomeprazole magnesium 20 mg +colloidal bismuth pectin 200mg+ amoxicillin 1000 mg + clarithromycin 500 mg, twice a day, for 14 days.

Patients who is still positive for H. pylori infection after the first line solution select the second line solution (high-dose dual regimen): esomeprazole magnesium 20 mg and amoxicillin 750 mg, 4 times daily, for 14 days.

Main study endpoint:

The difference in the eradication rate of H. pylori infection between the furazolidone quadruple regimen and the clarithromycin quadruple regimen.

Secondary study endpoint:

1. Safety and compliance of the furazolidone quadruple regimen. 2. Comparison of high-dose dual therapy with furazolidone quadruple therapy and clarithromycin quadruple therapy on H. pylori eradication rate. 3. 1-year recurrence and recurrence rate of H. pylori infection.

The 2 groups in the trial

  • furazolidone regimenTreatment being tested

    Patients who were enrolled in the experimental group use the furazolidone regimen esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid+ amoxicillin 1000 mg bid+ furazolidone 100 mg bid

    Treatment: Furazolidone

  • Clarithromycin regimenExisting treatment, for comparison

    Patients who were enrolled in the control group use the clarithromycin regimen esomeprazole magnesium 20 mg bid+colloidal bismuth pectin 200mg bid+ amoxicillin 1000 mg bid+ clarithromycin 500 mg bid

    Treatment: Clarithromycin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Furazolidone Containing Quadruple Therapy for First-line Helicobacter Pylori Eradication
Record updated
12 February 2025